retatrutide clinical trial weight loss results Retatrutide, Eli Lilly's next generation of injections, showed dramatic in trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight. Eli Retatrutide, a new weight loss

Semaglutide and similar medications are called glucagen-like-peptide-1 (GLP-1) agonists

Potential benefits and harms of novel antidiabetic drugs during COVID-19 crisis

10.1021/jf00051a039 140 KingM

Moreover, A double-blind study of patients with T2DM treated with metformin led to significant changes in the relative abundance of more than 80 bacterial species compared with placebo after 4 months, in which an increase in Escherichia and Akkermansia muciniphila and a decrease in Intestinibacter were also observed, whereas most of the changes with placebo occurred in phylum Firmicutes and phylum Proteobacteria (Wu et al., 2017)